DSCO, AZN, PWRM, - PennyOmega.com Stock Report!
Wednesday, May 19th, 2010
__
PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, PWRM has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro(R), a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, currently engaged in Phase II clinical trials.
These products are designed to analyze proteins and their mutations to assess an individual’s risk for developing disease later in life, a patient’s likelihood of responding to a particular drug, a patient’s risk of disease progression and disease recurrence, to measure a patient’s exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity.
** PWRM reported that it has filed two provisional patent applications with the United States Patent and Trademark Office (USPTO) – one on Alzheimer’s disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer’s disease patients.
These two provisional patent applications, along with the additional provisional patent application recently filed by the principals of PWRM and others on the use of stem cell protein biomarkers to monitor stem cell therapy and three other recently filed provisional patent applications on Parkinson’s and Alzheimer’s disease diagnosis, disclose a vast amount of invaluable information crucial to the accurate diagnosis and treatment of neurodegenerative diseases.
These provisional patent applications cover diagnosis, treatment options and therapy monitoring in neurodegenerative diseases. The combination of these disclosures forms a strong foundation for innovation in diagnosis and treatment for Alzheimer’s disease, and other diseases, through the genome and proteome of the patient, i.e., Personalized Regenerative Medicine (PRM).
More about PWRM at www.power3medical.com.
**************************************************************
DSCO, Discovery Laboratories, Inc.
DSCO is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing.
** DSCO reported that the revalidation of its optimized fetal rabbit Biological Activity Test (BAT, an important quality control release and stability test) has been completed, having met all pre-specified acceptance criteria.
The optimization and successful revalidation of the BAT is a key milestone in Discovery Labs’ plans to resolve the sole remaining Chemistry, Manufacturing & Control (CMC) issue necessary to potentially gain U.S. Food and Drug Administration (FDA) marketing approval for Surfaxin(R) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The safety and efficacy of Surfaxin for neonatal RDS has been previously demonstrated in a comprehensive Phase 3 clinical program.
If approved, Surfaxin would be the first synthetic, peptide-containing surfactant for commercial use in neonatal medicine.
More about DSCO at www.Discoverylabs.com.
**************************************************************
AZN, AstraZeneca PLC
AZN is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.
AZN reported that the company is collaborating with the Carolina Family Health Centers, Inc., to provide its medicines at no cost to qualifying patients. Patients referred to the center will only be required to pay a nominal dispensing fee to receive their AZN’s prescriptions at health center pharmacies.
**************************************************************
********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).
.png)
.png)
.png)
